Comparación de ciclos sub, super y ultracríticos para centrales termosolares

El presente proyecto fin de grado tiene como objetivo la comparación de ciclos subcríticos, supercríticos y ultracríticos en centrales termosolares. Para ello se ha realizado un programa que permite calcular las variables termodinámicas de interés (temperatura, presión, entalpía y gasto másico) en los puntos singulares del ciclo de producción de potencia, una vez introducidos los valores que permiten calcular el mismo. El programa calcula a su vez el rendimiento de la central y la potencia neta generada. Además del balance energético de cada ciclo de producción de potencia, el programa permite calcular los parámetros característicos de transferencia de calor de los intercambiadores cerrados que poseen los ciclos, así como sus dimensiones. Se comparan en total diez ciclos: ciclo subcrítico condensado por agua o aire, supercrítico condensado por agua o aire y con un solo o doble recalentamiento y ultracrítico condensado por agua o aire y con un solo o doble recalentamiento, introduciendo en el programa las condiciones propias de cada uno de ellos. Los ciclos subcríticos trabajan con ~125bar en el foco caliente y el vapor alcanza los 540°C. Estos ciclos son los utilizados hasta hoy para centrales termosolares. En los ciclos supercríticos la presión se eleva hasta los 300bar y la temperatura del vapor alcanza los 590°C, mientras que en los ciclos ultracríticos estos parámetros aumentan hasta los 330bar y 630°C. Por tanto, en estos dos últimos casos, se produce una transición continua desde el estado líquido al estado vapor ya que el cambio de fase no se produce a la temperatura de saturación. La utilización de mayores temperaturas permite mejorar la eficiencia que hoy día se tiene con los ciclos subcríticos: ~48% en ultracríticos frente a ~38% en subcríticos. Sin embargo la mayor parte de la mejora se obtiene al aumentar la temperatura a solo 590°C, propia de los supercríticos, con una rendimiento de ~46,5%. Al condensar por aire los ciclos muestran peores resultados, disminuyendo sus rendimientos del orden de un 2%, mientras que los ciclos con doble recalentamiento aumentan su eficiencia en un 0,2%. Los ciclos super y ultracríticos constan de un mayor número de intercambiadores cerrados que los subcríticos. De esta forma, aunque las condiciones sean más extremas en super y ultracríticos, los intercambiadores no se diferencian apenas de los de los ciclos subcríticos ya que la carga se reparte entre un mayor número de ellos.The present project aims for making a comparison between subcritical, supercritical and ultracritical cycles for power towers. To do so, it has been created a program that allows the calculation of some variables (temperature, pressure, enthalpy and flow rate) in the singular points of the power plant cycles, once the values that make possible the calculation have been introduced. This program calculates also the efficiency and the power generated by the plant. Apart from the cycles’ heat balance, the program allows the calculation of the characteristic parameters of the cycles’ feedwater heaters, and also the dimensions of them. In total ten cycles are compared: subcritical with wet and dry condenser cooling, supercritical with wet and dry condenser cooling and with only one and with two reheaters and ultracritical with wet and dry condenser cooling and with one and with two reheaters, introducing to make the comparison the specific thermal conditions of each cycle. Subcritial cycles work with 125bar in the hot focus and the steam reachs 540°C. Nowadays these are the cycles used in power towers. In supercritical cycles the pressure increases to 300bar and the steam reachs 590°C, whereas in ultracritical cycles these parameters increase to 330bar and 630°C. Therefore, in these two last cases, there is a continuous transition from liquid water to steam because of the phase change is not at the saturation temperature. The use of higher temperatures lets improve the efficiency that nowadays subcritical cycles have: ~48% in ultracritical cycles versus ~38% in subcritical. However, most of the improvement can be expected by raising the temperature to only 590°C, typical of supercritical cycles, with an efficiency ~46,5%. With dry condenser cooling, the cycles get worse results, decreasing their efficiency ~2%, whereas cycles with two reheaters increase their efficiency ~0,2%. Supercritical and ultracritical cycles have more feedwater heaters than subcritical cycles. By this way, although the conditions are more extreme in super and ultracritical cycles, there isn´t hardly any differences between super and ultracritical heat exchangers and subcritical heat exchangers because the load is divided in a higher number of them.Ingeniería en Tecnologías Industriale

Electricitat i magnetisme

Proposem diferents activitats que posen de manifest la relació entre electricitat i magnetisme

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks : A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Altres ajuts: Acord transformatiu CRUE-CSICData on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. The ojective of this study was to assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. A retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks was carried out in Spain. We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) psoriasis area severity index (PASI) had decreased from 11.1 (7.3) to 1.7 (2.8) (−9.3; [−10.2;-8.4]), 85.9% of the patients had achieved PASI score of 4 or less and 77.9% a PASI score of 2 or less. In terms of relative PASI response, 59.4% of the patients achieved a PASI-90 response and 49.0% a PASI-100 response. On multivariate analysis, two factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0.44; 95% CI, 0.22-0.88) and a greater previous exposure to biologic therapy (OR, 0.69; 95% CI, [0.56-0.84]). Adverse events were rare (9.9%) and led to withdrawal from treatment in only nine patients (2.6%) by the end of the follow-up period. The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. The ojective of this study was to assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. A retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks was carried out in Spain. We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) psoriasis area severity index (PASI) had decreased from 11.1 (7.3) to 1.7 (2.8) (-9.3; [-10.2;-8.4]), 85.9% of the patients had achieved PASI score of 4 or less and 77.9% a PASI score of 2 or less. In terms of relative PASI response, 59.4% of the patients achieved a PASI-90 response and 49.0% a PASI-100 response. On multivariate analysis, two factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0.44; 95% CI, 0.22-0.88) and a greater previous exposure to biologic therapy (OR, 0.69; 95% CI, [0.56-0.84]). Adverse events were rare (9.9%) and led to withdrawal from treatment in only nine patients (2.6%) by the end of the follow-up period. The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value

Adherence to the mediterranean lifestyle and desired body weight loss in a mediterranean adult population with overweight: a PREDIMED-Plus Study

Background: Body weight dissatisfaction is a hindrance to following a healthy lifestyle and it has been associated with weight concerns. Objectives: The aim of this study was to assess the association between the adherence to the Mediterranean lifestyle (diet and exercise) and the desired body weight loss in an adult Mediterranean population with overweight. Methods: Cross-sectional analysis in 6355 participants (3268 men; 3087 women) with metabolic syndrome and BMI (Body mass index) between 27.0 and 40.0 kg/m2 (55-75 years old) from the PREDIMED-Plus trial. Desired weight loss was the percentage of weight that participants wished to lose. It was categorized into four cut-offs of this percentage (Q1: <10%, n = 1495; Q2: 10-15%, n = 1804; Q3: <15-20%, n = 1470; Q4: ≥20%, n = 1589). Diet was assessed using a validated food frequency questionnaire and a 17-item Mediterranean diet questionnaire. Physical activity was assessed by the validated Minnesota-REGICOR and the validated Spanish version of the Nurses' Health Study questionnaire. Results: Participants reporting higher percentages of desired weight loss (Q3 and Q4) were younger, had higher real and perceived BMI and were more likely to have abdominal obesity. Desired weight loss correlated inversely to physical activity (Q1: 2106 MET min/week; Q4: 1585 MET min/week. p < 0.001) and adherence to Mediterranean diet (Q1: 8.7; Q4: 8.3. p < 0.001). Conclusions: In older Mediterranean individuals with weight excess, desired weight loss was inversely associated with Mediterranean lifestyle adherence. Deeply rooted aspects of the MedDiet remained similar across groups. Longitudinal research is advised to be able to establish causality.The PREDIMED-Plus trial was supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (five coordinated FIS projects led by J.S.-S. and J.Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, and PI19/01332, the Especial Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-Plus grant to J.S.-S., the European Research Council (Advanced Research Grant 2013–2018, 340918) to Miguel Ángel Martínez-González, the Recercaixa Grant to J.S.-S. (2013ACUP00194), Grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013, PS0358/2016, and PI0137/2018), a Grant from the Generalitat Valenciana (PROMETEO/2017/017), a SEMERGEN Grant, EU-COST Action CA16112, a Grant of support to research groups no. 35/2011 from the Balearic Islands Government, Grants from Balearic Islands Health Research Institute (IDISBA), funds from the European Regional Development Fund (CIBEROBN CB06/03 and CB12/03) and from the European Commission (EAT2BENICE_H2020_SFS2016). M. Rosa Bernal-López was supported by “Miguel Servet Type I” program (CP15/00028) from the ISCIII-Madrid (Spain), cofinanced by the European Regional Development Fund. Jordi Salas-Salvadó is partially supported by ICREA under the ICREA Academia programme. Cristina Bouzas received a Fernando Tarongí Bauzà PhD Grant. I.M Gimenez-Alba received a grant FPU from the Ministry of Science, Innovation and Univesities (reference FPU 18/01703). The funding sponsors had no role in the design of the study, in the collection, analyses, or interpretation of the data; in the writing of the manuscript, and in the decision to publish the results

Adherence to the Mediterranean Lifestyle and Desired Body Weight Loss in a Mediterranean Adult Population with Overweight: A PREDIMED-Plus Study

Background. Body weight dissatisfaction is a hindrance to following a healthy lifestyle and it has been associated with weight concerns. Objectives. The aim of this study was to assess the association between the adherence to the Mediterranean lifestyle (diet and exercise) and the desired body weight loss in an adult Mediterranean population with overweight. Methods. Cross-sectional analysis in 6355 participants (3268 men; 3087 women) with metabolic syndrome and BMI (Body mass index) between 27.0 and 40.0 kg/m2 (55–75 years old) from the PREDIMED-Plus trial. Desired weight loss was the percentage of weight that participants wished to lose. It was categorized into four cut-offs of this percentage (Q1: <10%, n = 1495; Q2: 10–15%, n = 1804; Q3: <15–20%, n = 1470; Q4: ≥20%, n = 1589)

Adherence to the Mediterranean Lifestyle and Desired Body Weight Loss in a Mediterranean Adult Population with Overweight: A PREDIMED-Plus Study

Background. Body weight dissatisfaction is a hindrance to following a healthy lifestyle and it has been associated with weight concerns. Objectives. The aim of this study was to assess the association between the adherence to the Mediterranean lifestyle (diet and exercise) and the desired body weight loss in an adult Mediterranean population with overweight. Methods. Cross-sectional analysis in 6355 participants (3268 men; 3087 women) with metabolic syndrome and BMI (Body mass index) between 27.0 and 40.0 kg/m2 (55–75 years old) from the PREDIMED-Plus trial. Desired weight loss was the percentage of weight that participants wished to lose. It was categorized into four cut-offs of this percentage (Q1: <10%, n = 1495; Q2: 10–15%, n = 1804; Q3: <15–20%, n = 1470; Q4: ≥20%, n = 1589)